ReviewLangenbeck's archives of surgery2011
The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.
Review in Langenbeck's archives of surgery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it, 161 citations in OpenAlex.
- Current state of knowledge on neuroendocrine small bowel tumours: non-systematic review of the literature based on one case.BMJ case reports · 2013Pooled it
- Trial
- Long-term survival and molecular heterogeneity of sporadic multifocal non-functional pancreatic neuroendocrine tumors.iScience · 2026Article
- Navigating the landscape of liver transplantation in neuroendocrine tumors: A comprehensive scoping review.World journal of transplantation · 2026Article
- Unusual presentation of jejunal carcinoid tumor with intussusception and vertebral metastasis: a case report.Discover oncology · 2026Article
- Article
- Textbook outcome following surgery for pancreatic neuroendocrine tumours: retrospective study.BJS open · 2025Article
- Multimodal Treatment Approach for Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms of the Gallbladder: A Patient with a Favorable Survival Outcome.Internal medicine (Tokyo, Japan) · 2025Article
- Infrared spectral analysis of gastrointestinal neuroendocrine tumors reveals diagnostic biomarkers.Scientific reports · 2025Article
- Article
- Gallbladder Neuroendocrine Neoplasms in Dogs and Humans.Veterinary sciences · 2024Review
- An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.International journal of molecular sciences · 2024Review
- [Clinical significance of neuroendocrine tumors : Incidence, symptoms, diagnosis, stage, and prognostic factors and their influence on disease management].Radiologie (Heidelberg, Germany) · 2024Review
- The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review.Biomedicines · 2024Review
- Radioligand therapy (RLT) used to treat cardiac metastasis of pancreatic neuroendocrine tumor.Clinical case reports · 2024Article
- The Role of Receptor-Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors.Cancers · 2023Review
- Article
- Somatostatin Receptor-PET/CT/MRI of Head and Neck Neuroendocrine Tumors.AJNR. American journal of neuroradiology · 2023Article
- The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the United States.Journal of endocrinological investigation · 2023Article
- The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses.Cancers · 2022Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundRecent data demonstrate that the incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has increased exponentially (overall ~500%) over the last three decades, thus refuting the erroneous concept of rarity. GEP-NETs comprise 2% of all malignancies and in terms of prevalence, are the second commonest gastrointestinal malignancy after colorectal cancer. Diagnosis is usually late since there is no biochemical screening test and symptoms are protean and overlooked. As a consequence, 60-80% exhibit metastases with a consequent suboptimal outcome. DISCUSSION: The gastrointestinal tract and pancreas exhibit ~17 different neuroendocrine cell types, but neither the cell of origin nor the biological basis of GEP-NETs is understood. This review examines GEP-NETs from the cellular and molecular perspective and addresses the distinct patterns of functional tumor biology pertinent to clinicians. Although grouped as a neoplastic entity (NETs), each lesion is derived from distinct cell precursors, produces specific bioactive products, exhibits distinct chromosomal abnormalities and somatic mutation events and has uniquely dissimilar clinical presentations. GEP-NETs demonstrate very different survival rates reflecting the intrinsic differences in malignant potential and variations in proliferative regulation. Apart from the identification of the inhibitory role of the somatostatin receptors, there is limited biological knowledge of the key regulators of proliferation and hence a paucity of successful targeted therapeutic agents. IGF-I, TGFβ and a variety of tyrosine kinases have been postulated as key regulatory elements; rigorous data is still required to define predictably effective and rational therapeutic strategy in an individual tumor. A critical issue in the clinical management of GEP-NETs is the need to appreciate both the neuroendocrine commonalities of the disease as well as the unique characteristics of each tumor. The further acquisition of a detailed biological and molecular appreciation of GEP-NETs is vital to the development of effective management strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.